Novartis launches Jakavi in 50+ countries; J&J to market hep C drug in Europe;

> Novartis ($NVS) has launched myelofibrosis drug Jakavi in Singapore and 50 other countries. Report

> Johnson & Johnson's ($JNJ) Janssen has won EU marketing authorization for hep C drug Olysio. Release

> Tolmar Pharma has regained marketing rights for prostate cancer drug Eligard in the U.S. and Puerto Rico. More

> A new report highlights the meningococcal vaccines market through 2019. Release

And Finally... Some tech companies are betting that sifting through patients' social media posts will yield critical side-effect insights that drugmakers will buy. More

Suggested Articles

After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.